Vlada Melnikova
Plus aucun poste en cours
Profil
Vlada Melnikova worked as Director of Research & Development at ApoCell, Inc. She was also Vice President of Laboratory Services at Transgenomic, Inc. from 2013 to 2014 and Vice President of Clinical & Translational Affairs at Cardiff Oncology, Inc. from 2014 to 2016.
Melnikova holds a doctorate degree from Russian State Medical University and Henri Poincaré University.
Anciens postes connus de Vlada Melnikova
| Sociétés | Poste | Fin |
|---|---|---|
| CARDIFF ONCOLOGY, INC. | Directeur Technique/Scientifique/R&D | 01/10/2016 |
Transgenomic, Inc.
 Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Corporate Officer/Principal | 01/04/2014 |
ApoCell, Inc.
 ApoCell, Inc. Medical/Nursing ServicesHealth Services ApoCell, Inc. engages in molecular biomarker detection. It offers platform technologies, assay development, circulating tumor cells, genomics, flow cytometry, FISH and immunohistochemistry, immunofluorescence image analysis and cytokine Profiling services. The company was founded by Darren W. Davis in 2004 and is headquartered in Houston, TX. | Directeur Technique/Scientifique/R&D | - |
Formation de Vlada Melnikova
| Russian State Medical University | Doctorate Degree |
| Henri Poincaré University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARDIFF ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
ApoCell, Inc.
ApoCell, Inc. Medical/Nursing ServicesHealth Services ApoCell, Inc. engages in molecular biomarker detection. It offers platform technologies, assay development, circulating tumor cells, genomics, flow cytometry, FISH and immunohistochemistry, immunofluorescence image analysis and cytokine Profiling services. The company was founded by Darren W. Davis in 2004 and is headquartered in Houston, TX. | Health Services |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Health Technology |
